Randomised, quadruple-blind, parallel Phase IV study (n=27) comparing ketamine (0.75 mg/kg IV) versus propofol (1 mg/kg IV) as anaesthetic agents for ECT in treatment-resistant major depressive disorder.
This parallel-group randomised trial tests whether ketamine as the anaesthetic for ECT improves depressive symptoms compared with propofol in patients with treatment-resistant depression.
Patients receive anaesthesia with ketamine 0.75 mg/kg IV or propofol 1 mg/kg IV, both with remifentanil 1 mcg/kg; efficacy assessed by MADRS and clinical measures.
Planned interim safety analyses were described after 20 and 40 patients; an independent safety committee reviews adverse events and may adjust dosing or discontinue the trial.
Ketamine anesthesia for ECT with remifentanil co-administration.
Ketamine 0.75 mg/kg IV with remifentanil 1 mcg/kg IV.
Propofol anesthesia for ECT with remifentanil co-administration.
Propofol 1 mg/kg IV with remifentanil 1 mcg/kg IV; comparator stored as placeholder compound.